Related Experiment Video
Updated: May 6, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
10.8K
Prostate-specific Membrane Antigen-PET/CT in Nonprostatic Malignancies: Potential Applications in Theranostics
Priyanka Verma1,2, Sandip Basu1,2
1Professor, Clinical Nuclear Medicine, Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Jerbai Wadia Road, Parel.
Clinical Nuclear Medicine
|May 4, 2026
Summary
68Gallium-prostate-specific membrane antigen (PSMA) PET/CT is a key imaging tool for prostate cancer. This review explores PSMA PET/CT
Area of Science:
- Nuclear Medicine
- Oncology
- Radiochemistry
Background:
- Prostate-specific membrane antigen (PSMA) is a protein highly expressed in prostate cancer cells.
- PSMA is also found in the tumor neovasculature of various nonprostate cancers.
- 68Gallium-PSMA PET/CT is an advanced imaging technique utilizing this specific antigen.
Purpose of the Study:
- To review the clinical applications of PSMA PET/CT in various cancers beyond prostate carcinoma.
- To evaluate the diagnostic and therapeutic potential of PSMA-based imaging in nonprostate malignancies.
- To highlight the importance of understanding PSMA expression in both cancerous and benign conditions.
Main Methods:
- Literature review of studies investigating PSMA PET/CT in diverse cancers.
- Analysis of diagnostic performance and therapeutic implications of PSMA PET/CT.
- Comparison with other imaging modalities like 18F-fluorodeoxyglucose PET/CT.
Main Results:
- PSMA PET/CT shows promising results in imaging nonprostate malignancies such as glioma, renal cell carcinoma, and lung cancer.
- In some cases, PSMA PET/CT offers superior imaging results compared to 18F-fluorodeoxyglucose PET/CT.
- Awareness of benign conditions with PSMA uptake is crucial for accurate interpretation.
Conclusions:
- PSMA PET/CT is a versatile imaging modality with expanding applications in oncology.
- Further evaluation of specific indications and potential therapeutic uses is warranted.
- Careful interpretation considering benign PSMA uptake is essential for clinical utility.
Related Concept Videos
01:29Positron Emission Tomography
6.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.2K
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
861
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
861